Skip to main content

Table 2 Clinical characteristics and outcomes of patients with CCNE1-amplified tumors in the “Discovery-TNBC” cohort

From: CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer

Patient ID Age Stage (Neo)Adjuvant chemotherapy Response to neoadjuvant chemotherapy Adjuvant radiation RFS (months) OS (months)
1 50 I Declined N/A No 58 N/A
2 50 III TAC ypT2N0Mx No 11 23
3 46 III AC Carbo/nab-paclitaxel ypT3N1Mx Yes 24 55
4 36 III AC-T ypT0N1Mx Yes 13 18
5 35 III Carbo/taxol ypT3N2aMx Yes 3 21
6 46 III Carbo/taxol ypT3N3aMx Yes 13 43
7 50 II Docetaxel, cisplatin ypT1N1Mx Yes 8 15
8 46 III Carbo/taxol, AC ypT2N2aMx Yes 11 20
9 36 II Carbo/nab-paclitaxel ypT1cN0Mx Yes 8 24
10 55 III AC-T (adjuvant) pT4N2aMx No 46 60
11 46 II Carbo/taxol (adjuvant) pT2N1Mx No 21 34
12 53 III AC-T ypT1N1aMx No 9 16
13 48 II TC ypT1cN1Mx Yes 3 38
  1. AC adriamycin/cyclophosphamide, AC-T adriamycin/cyclophosphamide followed by paclitaxel, Carbo/taxol carboplatin/paclitaxel, TAC docetaxel/adriamycin/cyclophosphamide, TC docetaxel /cyclophosphamide, RFS relapse-free survival (surgery to first relapse), OS overall survival (surgery to death)